Leerink Partnrs Has Pessimistic View of TNYA FY2025 Earnings

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Analysts at Leerink Partnrs dropped their FY2025 earnings per share estimates for shares of Tenaya Therapeutics in a research note issued to investors on Wednesday, August 6th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($0.71) for the year, down from their prior estimate of ($0.70). The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Tenaya Therapeutics’ Q4 2025 earnings at ($0.18) EPS and FY2026 earnings at ($0.67) EPS.

Several other equities analysts also recently weighed in on TNYA. Chardan Capital reiterated a “buy” rating and set a $9.00 target price on shares of Tenaya Therapeutics in a research report on Thursday, August 7th. Wall Street Zen upgraded Tenaya Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Tenaya Therapeutics in a research report on Friday, April 25th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $6.25.

Tenaya Therapeutics Trading Up 11.1%

Tenaya Therapeutics stock opened at $0.76 on Monday. The stock has a market cap of $123.38 million, a PE ratio of -0.79 and a beta of 3.01. The stock has a 50-day moving average price of $0.68 and a 200 day moving average price of $0.66. Tenaya Therapeutics has a 52 week low of $0.36 and a 52 week high of $4.01.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.06.

Hedge Funds Weigh In On Tenaya Therapeutics

Large investors have recently modified their holdings of the company. DAFNA Capital Management LLC purchased a new position in shares of Tenaya Therapeutics in the 1st quarter worth about $27,000. Woodline Partners LP purchased a new position in shares of Tenaya Therapeutics in the 4th quarter worth about $28,000. Commerce Bank purchased a new stake in shares of Tenaya Therapeutics during the 4th quarter valued at about $29,000. Mariner LLC purchased a new stake in shares of Tenaya Therapeutics during the 4th quarter valued at about $30,000. Finally, Ground Swell Capital LLC purchased a new stake in shares of Tenaya Therapeutics during the 4th quarter valued at about $32,000. 90.54% of the stock is currently owned by hedge funds and other institutional investors.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.